Evommune Announces $115 Million Series C Financing to Accelerate Advancement of Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases
– Financing co-led by RA Capital Management and Sectoral Asset Management – – Proceeds to support clinical development of lead program MRGPRX2 inhibitor, EVO756, as well as IL-18 targeted fusion protein program, EVO301 – –…